{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:16:33Z","timestamp":1761178593622,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.canrad.2022.06.027","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T07:49:54Z","timestamp":1661327394000},"page":"955-961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immuno-radioth\u00e9rapie\u00a0: une revue du rationnel, d\u00e9veloppements cliniques r\u00e9cents et perspectives futures"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3386-8829","authenticated-orcid":false,"given":"R.","family":"Serre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Pointreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2022.06.027_bib0140","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway: Fig.\u00a01","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2022.06.027_bib0145","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.canrad.2022.06.027_bib0150","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","article-title":"Low-dose irradiation programs macrophage differentiation to an iNOS+\/M1\u00a0phenotype that orchestrates effective T cell immunotherapy","volume":"24","author":"Klug","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canrad.2022.06.027_bib0155","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1111\/bcp.14351","article-title":"Radiation therapy and the innate immune response: clinical implications for immunotherapy approaches","volume":"86","author":"G\u00f3mez","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.canrad.2022.06.027_bib0160","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-020-0942-3","article-title":"Radiation-induced bystander and abscopal effects: important lessons from preclinical models","volume":"123","author":"Daguenet","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2022.06.027_bib0165","doi-asserted-by":"crossref","first-page":"31812","DOI":"10.18632\/oncotarget.25746","article-title":"Immunologically effective dose: a practical model for immuno-radiotherapy","volume":"9","author":"Serre","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canrad.2022.06.027_bib0170","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2022.06.027_bib0175","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.06.027_bib0180","article-title":"Timing of adjuvant durvalumab initiation is not associated with outcomes in stage III non-small cell lung cancer","author":"Bryant","year":"2022","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.06.027_bib0185","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2022.06.027_bib0190","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2022.06.027_bib0195","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2022.06.027_bib0200","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3\u00a0trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2022.06.027_bib0205","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2022.06.027_bib0210","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/1759-7714.13044","article-title":"Radiotherapy is an independent prognostic marker of favorable prognosis in non\u2013small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab","volume":"10","author":"Yamaguchi","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.canrad.2022.06.027_bib0215","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","article-title":"Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone","volume":"18","author":"Koller","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.canrad.2022.06.027_bib0220","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","article-title":"A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma","volume":"96","author":"Hiniker","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.06.027_bib0225","doi-asserted-by":"crossref","first-page":"e28780","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canrad.2022.06.027_bib0230","doi-asserted-by":"crossref","first-page":"e002485","DOI":"10.1136\/jitc-2021-002485","article-title":"Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Leidner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canrad.2022.06.027_bib0235","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment with PD-1\u00a0and CTLA-4\u00a0immune checkpoint inhibitors and palliative radiation therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2022.06.027_bib0240","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1\u00a0blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2022.06.027_bib0245","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1\u00a0treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.canrad.2022.06.027_bib0250","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1\u00a0and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canrad.2022.06.027_bib0255","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2022.06.027_bib0260","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1\u00a0regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.canrad.2022.06.027_bib0265","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2022.06.027_bib0135","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4\u00a0antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321822001317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321822001317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:37:03Z","timestamp":1761136623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321822001317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1278321822001317"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2022.06.027","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immuno-radioth\u00e9rapie\u00a0: une revue du rationnel, d\u00e9veloppements cliniques r\u00e9cents et perspectives futures","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2022.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}